Literature DB >> 23949829

Atypical aging in Down syndrome.

Warren B Zigman1.   

Abstract

At present, there may be over 210,000 people with Down syndrome (DS) over the age of 55 in the United States (US) who have significant needs for augmented services due to circumstances related to ordinary and/or pathological aging. From 1979 through 2003, the birth prevalence of DS rose from 9.0 to 11.8 (31.1%) per 10,000 live births in 10 representative US regions. This increase, largely due to women conceiving after age 35, portends an ever-growing population of people with DS who may be subject to pathogenic aging. Whereas Trisomy 21 is one of the most widespread genetic causes of intellectual disability (ID), it still is one of the least understood of all genetic ID syndromes. While longevity in people with DS has improved appreciably in as modest a period as 30 years, age-specific risk for mortality still is considerably increased compared both with other people with ID or with the typically developing population. The penetrance of the phenotype is widely distributed, even though a consistent genotype is assumed in 95% of the cases. Some, but not all body systems, exhibit signs of premature or accelerated aging. This may be due to both genetic and epigenetic inheritance. We now know that the long-term outcome for people with DS is not as ominous as once contemplated; a number of people with DS are living into their late 60s and 70s with few if any major signs of pathogenic aging. Alzheimer's disease (AD), a devastating disease that robs a person of their memory, abilities and personality, is particularly common in elder adults with DS, but is not a certainty as originally thought, some 20% to 30% of elder adults with DS might never show any, or at most mild signs of AD. DS has been called a mature well-understood syndrome, not in need of further research or science funding. We are only beginning to understand how epigenetics affects the phenotype and it may be feasible in the future to alter the phenotype through epigenetic interventions. This chapter is divided into two sections. The first section will review typical and atypical aging patterns in somatic issues in elder adults with DS; the second section will review the multifaceted relationship between AD and DS.
Copyright © 2013 Wiley Periodicals, Inc., a Wiley company.

Entities:  

Keywords:  Alzheimer's disease; Down syndrome; accelerated aging; aging; dementia; epigenetics; trisomy 21

Mesh:

Substances:

Year:  2013        PMID: 23949829     DOI: 10.1002/ddrr.1128

Source DB:  PubMed          Journal:  Dev Disabil Res Rev        ISSN: 1940-5529


  84 in total

Review 1.  Cerebrovascular contributions to aging and Alzheimer's disease in Down syndrome.

Authors:  Donna M Wilcock; Frederick A Schmitt; Elizabeth Head
Journal:  Biochim Biophys Acta       Date:  2015-11-26

2.  The amyloid precursor protein (APP) intracellular domain regulates translation of p44, a short isoform of p53, through an IRES-dependent mechanism.

Authors:  Mi Li; Mariana Pehar; Yan Liu; Anita Bhattacharyya; Su-Chun Zhang; Kenneth J O'Riordan; Corinna Burger; Luciano D'Adamio; Luigi Puglielli
Journal:  Neurobiol Aging       Date:  2015-06-21       Impact factor: 4.673

3.  Telomere shortening in Down syndrome patients--when does it start?

Authors:  Aleksandra Gruszecka; Przemysław Kopczyński; Dorota Cudziło; Natalia Lipińska; Aleksandra Romaniuk; Wojciech Barczak; Natalia Rozwadowska; Ewa Totoń; Błażej Rubiś
Journal:  DNA Cell Biol       Date:  2015-03-18       Impact factor: 3.311

4.  Designer receptors enhance memory in a mouse model of Down syndrome.

Authors:  Ashley M Fortress; Eric D Hamlett; Elena M Vazey; Gary Aston-Jones; Wayne A Cass; Heather A Boger; Ann-Charlotte E Granholm
Journal:  J Neurosci       Date:  2015-01-28       Impact factor: 6.167

Review 5.  Aneuploidy and skeletal health.

Authors:  Archana Kamalakar; John R Harris; Kent D McKelvey; Larry J Suva
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

6.  Alzheimer-Like Pattern of Hypometabolism Emerges with Elevated Amyloid-β Burden in Down Syndrome.

Authors:  Patrick J Lao; Ben L Handen; Tobey J Betthauser; Iulia Mihaila; Sigan L Hartley; Annie D Cohen; Dana L Tudorascu; Peter D Bulova; Brian J Lopresti; Rameshwari V Tumuluru; Dhanabalan Murali; Chester A Mathis; Todd E Barnhart; Charles K Stone; Julie C Price; Darlynne A Devenny; Sterling C Johnson; William E Klunk; Bradley T Christian
Journal:  J Alzheimers Dis       Date:  2018       Impact factor: 4.472

7.  Analysis of Heteroplasmic Variants in the Cardiac Mitochondrial Genome of Individuals with Down Syndrome.

Authors:  Erik Hefti; Jonathan Bard; Javier G Blanco
Journal:  Hum Mutat       Date:  2016-09-26       Impact factor: 4.878

8.  Microbleeds and Cerebral Amyloid Angiopathy in the Brains of People with Down Syndrome with Alzheimer's Disease.

Authors:  Alex M Helman; Morgan Siever; Katie L McCarty; Ira T Lott; Eric Doran; Erin L Abner; Frederick A Schmitt; Elizabeth Head
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

Review 9.  Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.

Authors:  Elizabeth Head; Ira T Lott; Donna M Wilcock; Cynthia A Lemere
Journal:  Curr Alzheimer Res       Date:  2016       Impact factor: 3.498

Review 10.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.